{"id":2564,"date":"2025-10-15T14:42:29","date_gmt":"2025-10-15T13:42:29","guid":{"rendered":"https:\/\/lenus-healthcare.com\/?p=2564"},"modified":"2025-10-15T14:42:29","modified_gmt":"2025-10-15T13:42:29","slug":"breast-cancer","status":"publish","type":"post","link":"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/","title":{"rendered":"FDA Approval of Imlunestrant for ER-Positive, HER2-Negative, ESR1-Mutated Breast Cancer"},"content":{"rendered":"

Metastatic breast cancer with estrogen receptor positivity (ER-positive) and HER2 negativity represents one of the most common and challenging subtypes of breast cancer. In many patients, mutations in the ESR1<\/strong> gene result in resistance to endocrine therapies, making long-term disease control difficult.<\/p>\n

On September 25, 2025, the U.S. Food and Drug Administration (FDA) approved Imlunestrant (Inluriyo, Eli Lilly and Company)<\/strong>, an estrogen receptor antagonist, for the treatment of adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease has progressed following at least one line of endocrine therapy.<\/p>\n

This approval was based on results from the EMBER-3 clinical trial (NCT04975308)<\/strong>, which demonstrated improved efficacy and safety of Imlunestrant compared with standard endocrine therapy options (FDA, 2025).<\/p>\n

Table of Contents<\/strong><\/p>\n

    \n
  1. Introduction to Imlunestrant and Mechanism of Action<\/a><\/li>\n
  2. EMBER-3 Clinical Trial<\/a><\/li>\n
  3. Dosage and Administration<\/a><\/li>\n
  4. Common Adverse Events<\/a><\/li>\n
  5. Role of Guardant360 CDx as Companion Diagnostic<\/a><\/li>\n
  6. FDA Expedited Programs<\/a><\/li>\n
  7. Conclusion and Future Perspectives<\/a><\/li>\n
  8. Frequently Asked Questions (FAQs)<\/a><\/li>\n<\/ol>\n

    1. Introduction to Imlunestrant and Mechanism of Action<\/h2>\n

    Imlunestrant (Inluriyo)<\/strong> is a selective estrogen receptor antagonist that effectively inhibits estrogen receptor signaling pathways. It is particularly beneficial for patients with ESR1 mutations<\/strong>, which are associated with resistance to conventional endocrine therapies (FDA, 2025).<\/p>\n

    2. EMBER-3 Clinical Trial<\/h2>\n

    2.1 Study Design<\/strong><\/p>\n

    The EMBER-3 trial was a randomized, open-label, multicenter study that enrolled 874 patients<\/strong> with ER-positive, HER2-negative breast cancer. All patients had previously received treatment with an aromatase inhibitor, either alone or in combination with a CDK4\/6 inhibitor.<\/p>\n

    Patients were randomized into three study arms:<\/p>\n

      \n
    1. Imlunestrant<\/li>\n
    2. Investigator\u2019s choice of Fulvestrant or Exemestane<\/li>\n
    3. An investigational combination regimen<\/li>\n<\/ol>\n

      2.2 Key Efficacy Outcomes<\/strong><\/p>\n

        \n
      • Progression-Free Survival (PFS):<\/strong> In patients with ESR1 mutations, PFS was 5.5 months with Imlunestrant vs. 3.8 months with standard endocrine therapy (HR = 0.62; p = 0.0008).<\/li>\n
      • Objective Response Rate (ORR):<\/strong> 14.3% with Imlunestrant vs. 7.7% with standard therapy.<\/li>\n
      • Overall Survival (OS):<\/strong> Data were immature at the time of analysis, with 31% mortality reported (ClinicalTrials.gov, NCT04975308).<\/li>\n<\/ul>\n

        These findings demonstrated significant clinical benefit of Imlunestrant in the ESR1-mutated population.<\/p>\n

        3. Dosage and Administration<\/h2>\n
          \n
        • Recommended dose:<\/strong> 400 mg orally once daily<\/li>\n
        • Administration:<\/strong> On an empty stomach (at least 2 hours before or 1 hour after food)<\/li>\n
        • Duration:<\/strong> Continue until disease progression or unacceptable toxicity (FDA, 2025).<\/li>\n<\/ul>\n

          4. Common Adverse Events<\/h2>\n

          The most frequently reported adverse events (\u226510%) include:<\/p>\n

            \n
          • Decreased hemoglobin<\/li>\n
          • Musculoskeletal pain<\/li>\n
          • Fatigue<\/li>\n
          • Diarrhea, nausea, and constipation<\/li>\n
          • Laboratory abnormalities (elevated liver enzymes, triglycerides, cholesterol, and decreased white blood cells)<\/li>\n<\/ul>\n

            All serious adverse events should be reported via the FDA MedWatch Reporting System<\/strong>.<\/p>\n

            5. Role of Guardant360 CDx<\/h2>\n

            Concurrently with drug approval, the Guardant360 CDx assay<\/strong> was authorized as a companion diagnostic<\/strong>. This ctDNA-based test detects ESR1 mutations<\/strong> in the ligand-binding domain of the estrogen receptor, enabling identification of patients eligible for Imlunestrant therapy.<\/p>\n

            6. FDA Expedited Programs<\/h2>\n
              \n
            • Fast Track Designation<\/strong> to accelerate review<\/li>\n
            • Use of the Assessment Aid<\/strong> to streamline FDA evaluation<\/li>\n
            • Establishes a framework for future development of targeted therapies in metastatic breast cancer.<\/li>\n<\/ul>\n

              7. Conclusion and Future Perspectives<\/strong><\/p>\n

              The FDA approval of Imlunestrant<\/strong> represents a major advancement in the treatment of patients with ER-positive, HER2-negative, ESR1-mutated breast cancer<\/strong>. By improving progression-free survival and response rates compared with standard endocrine therapies, Imlunestrant offers a promising new treatment option. However, continued monitoring of long-term survival and safety data will be critical in shaping its role in clinical practice.<\/p>\n

              8. Frequently Asked Questions (FAQs)<\/strong><\/p>\n

                \n
              • Who is eligible for Imlunestrant therapy?<\/strong>
                \nAdults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer who have experienced disease progression following endocrine therapy.<\/li>\n
              • How does Imlunestrant differ from Fulvestrant or Exemestane?<\/strong>
                \nUnlike Fulvestrant or Exemestane, Imlunestrant is specifically designed to target ESR1-mutated tumors and has demonstrated superior efficacy in this subgroup.<\/li>\n
              • How are patients selected for Imlunestrant treatment?<\/strong>
                \nUsing the Guardant360 CDx assay<\/strong>, which identifies ESR1 mutations in circulating tumor DNA.<\/li>\n
              • What is the recommended dosage?<\/strong>
                \n400 mg orally once daily on an empty stomach.<\/li>\n
              • What are the most common side effects?<\/strong>
                \nFatigue, musculoskeletal pain, gastrointestinal disturbances, and laboratory abnormalities (e.g., elevated liver enzymes, decreased blood counts).<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"

                FDA Approval of Imlunestrant for ESR1-Mutated Breast Cancer<\/p>\n","protected":false},"author":2,"featured_media":2574,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_joinchat":[],"footnotes":""},"categories":[120],"tags":[],"class_list":["post-2564","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-new-medicine"],"acf":[],"yoast_head":"\nFDA Approval of Imlunestrant for ESR1-Mutated Breast Cancer<\/title>\n<meta name=\"description\" content=\"FDA approved Imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Approval of Imlunestrant for ESR1-Mutated Breast Cancer\" \/>\n<meta property=\"og:description\" content=\"FDA approved Imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/\" \/>\n<meta property=\"og:site_name\" content=\"Lenus Health\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-15T13:42:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2025\/10\/brast-cancerTH.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1600\" \/>\n\t<meta property=\"og:image:height\" content=\"873\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"login-hashemzadeh-dash\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"login-hashemzadeh-dash\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/\"},\"author\":{\"name\":\"login-hashemzadeh-dash\",\"@id\":\"https:\/\/lenus-healthcare.com\/#\/schema\/person\/0abed38587372602833862aaf8e51e09\"},\"headline\":\"FDA Approval of Imlunestrant for ER-Positive, HER2-Negative, ESR1-Mutated Breast Cancer\",\"datePublished\":\"2025-10-15T13:42:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/\"},\"wordCount\":658,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/lenus-healthcare.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2025\/10\/brast-cancerTH.jpg\",\"articleSection\":[\"New medicines\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/\",\"url\":\"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/\",\"name\":\"FDA Approval of Imlunestrant for ESR1-Mutated Breast Cancer\",\"isPartOf\":{\"@id\":\"https:\/\/lenus-healthcare.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2025\/10\/brast-cancerTH.jpg\",\"datePublished\":\"2025-10-15T13:42:29+00:00\",\"description\":\"FDA approved Imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.\",\"breadcrumb\":{\"@id\":\"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/#primaryimage\",\"url\":\"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2025\/10\/brast-cancerTH.jpg\",\"contentUrl\":\"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2025\/10\/brast-cancerTH.jpg\",\"width\":1600,\"height\":873},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/lenus-healthcare.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New medicines\",\"item\":\"https:\/\/lenus-healthcare.com\/en\/category\/new-medicine\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"FDA Approval of Imlunestrant for ER-Positive, HER2-Negative, ESR1-Mutated Breast Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/lenus-healthcare.com\/#website\",\"url\":\"https:\/\/lenus-healthcare.com\/\",\"name\":\"Lenus Health\",\"description\":\"Lenus Health Gmbh | Berlin\",\"publisher\":{\"@id\":\"https:\/\/lenus-healthcare.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/lenus-healthcare.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/lenus-healthcare.com\/#organization\",\"name\":\"Lenus Health\",\"url\":\"https:\/\/lenus-healthcare.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/lenus-healthcare.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2017\/07\/Logo-pur.webp\",\"contentUrl\":\"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2017\/07\/Logo-pur.webp\",\"width\":1275,\"height\":298,\"caption\":\"Lenus Health\"},\"image\":{\"@id\":\"https:\/\/lenus-healthcare.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/lenus-healthcare.com\/#\/schema\/person\/0abed38587372602833862aaf8e51e09\",\"name\":\"login-hashemzadeh-dash\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/lenus-healthcare.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/b58400e93864034c4119dff6d018160c0ebf646c52f088b18a3bde50dc9174f6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/b58400e93864034c4119dff6d018160c0ebf646c52f088b18a3bde50dc9174f6?s=96&d=mm&r=g\",\"caption\":\"login-hashemzadeh-dash\"},\"url\":\"https:\/\/lenus-healthcare.com\/en\/author\/login-hashemzadeh-dash\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Approval of Imlunestrant for ESR1-Mutated Breast Cancer","description":"FDA approved Imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/","og_locale":"en_US","og_type":"article","og_title":"FDA Approval of Imlunestrant for ESR1-Mutated Breast Cancer","og_description":"FDA approved Imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.","og_url":"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/","og_site_name":"Lenus Health","article_published_time":"2025-10-15T13:42:29+00:00","og_image":[{"width":1600,"height":873,"url":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2025\/10\/brast-cancerTH.jpg","type":"image\/jpeg"}],"author":"login-hashemzadeh-dash","twitter_card":"summary_large_image","twitter_misc":{"Written by":"login-hashemzadeh-dash","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/#article","isPartOf":{"@id":"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/"},"author":{"name":"login-hashemzadeh-dash","@id":"https:\/\/lenus-healthcare.com\/#\/schema\/person\/0abed38587372602833862aaf8e51e09"},"headline":"FDA Approval of Imlunestrant for ER-Positive, HER2-Negative, ESR1-Mutated Breast Cancer","datePublished":"2025-10-15T13:42:29+00:00","mainEntityOfPage":{"@id":"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/"},"wordCount":658,"commentCount":0,"publisher":{"@id":"https:\/\/lenus-healthcare.com\/#organization"},"image":{"@id":"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2025\/10\/brast-cancerTH.jpg","articleSection":["New medicines"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/lenus-healthcare.com\/en\/breast-cancer\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/","url":"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/","name":"FDA Approval of Imlunestrant for ESR1-Mutated Breast Cancer","isPartOf":{"@id":"https:\/\/lenus-healthcare.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/#primaryimage"},"image":{"@id":"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/#primaryimage"},"thumbnailUrl":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2025\/10\/brast-cancerTH.jpg","datePublished":"2025-10-15T13:42:29+00:00","description":"FDA approved Imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.","breadcrumb":{"@id":"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lenus-healthcare.com\/en\/breast-cancer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/#primaryimage","url":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2025\/10\/brast-cancerTH.jpg","contentUrl":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2025\/10\/brast-cancerTH.jpg","width":1600,"height":873},{"@type":"BreadcrumbList","@id":"https:\/\/lenus-healthcare.com\/en\/breast-cancer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/lenus-healthcare.com\/en\/"},{"@type":"ListItem","position":2,"name":"New medicines","item":"https:\/\/lenus-healthcare.com\/en\/category\/new-medicine\/"},{"@type":"ListItem","position":3,"name":"FDA Approval of Imlunestrant for ER-Positive, HER2-Negative, ESR1-Mutated Breast Cancer"}]},{"@type":"WebSite","@id":"https:\/\/lenus-healthcare.com\/#website","url":"https:\/\/lenus-healthcare.com\/","name":"Lenus Health","description":"Lenus Health Gmbh | Berlin","publisher":{"@id":"https:\/\/lenus-healthcare.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lenus-healthcare.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/lenus-healthcare.com\/#organization","name":"Lenus Health","url":"https:\/\/lenus-healthcare.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lenus-healthcare.com\/#\/schema\/logo\/image\/","url":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2017\/07\/Logo-pur.webp","contentUrl":"https:\/\/lenus-healthcare.com\/wp-content\/uploads\/2017\/07\/Logo-pur.webp","width":1275,"height":298,"caption":"Lenus Health"},"image":{"@id":"https:\/\/lenus-healthcare.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/lenus-healthcare.com\/#\/schema\/person\/0abed38587372602833862aaf8e51e09","name":"login-hashemzadeh-dash","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/lenus-healthcare.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/b58400e93864034c4119dff6d018160c0ebf646c52f088b18a3bde50dc9174f6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b58400e93864034c4119dff6d018160c0ebf646c52f088b18a3bde50dc9174f6?s=96&d=mm&r=g","caption":"login-hashemzadeh-dash"},"url":"https:\/\/lenus-healthcare.com\/en\/author\/login-hashemzadeh-dash\/"}]}},"_links":{"self":[{"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/posts\/2564","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/comments?post=2564"}],"version-history":[{"count":3,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/posts\/2564\/revisions"}],"predecessor-version":[{"id":2571,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/posts\/2564\/revisions\/2571"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/media\/2574"}],"wp:attachment":[{"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/media?parent=2564"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/categories?post=2564"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lenus-healthcare.com\/en\/wp-json\/wp\/v2\/tags?post=2564"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}